Loss of skeletal muscle mass and strength is apparent as early as the 4th decade of life and
progresses linearly with increasing age [1, 2]. The term sarcopenia, first introduced by Irwin …

Sarcopenia is a complex syndrome defined by progressive and generalized loss of skeletal
muscle mass and strength. Although sarcopenia is mainly associated with aging, cancer is …

Background & aims The purpose of this meta-analysis was to summarize the published data
regarding associations between occurrence of severe treatment related toxicity and low …

Fluoropyrimidines are widely used in the treatment of several types of solid tumors. Although
most often well tolerated, severe toxicity is encountered in~ 20–30% of the patients …

This study will address the prevalence of pre-therapeutic sarcopenia (PS) and its clinical
impact during cancer treatment among adult cancer patients≥ 18 years of age. A meta …

Introduction Age-associated physiological changes can alter the disposition of drugs,
however, pathophysiological changes associated with geriatric syndromes in older adults …

Background Chemotherapy is an effective treatment with good clinical response in patients
with cancer. However, it can cause exacerbated toxicities in patients and consequently …

Rationale and Objectives Sarcopenia is defined as skeletal muscle loss and can be
assessed by cross-sectional imaging. Our aim was to establish the effect of sarcopenia on …

Low skeletal muscle mass is highly prevalent in older cancer patients and affects 5% to 89%
depending on the type and stage of cancer. Low skeletal muscle mass is associated with …

Background & aims A low muscle mass before start of treatment and loss of muscle mass
during chemotherapy is related to adverse outcomes in patients with cancer. In this …